Adjunctive intrapleural therapies have been developed to improve outcomes in empyema, with intrapleural fibrinolytics, such as streptokinase or tissue plasminogen activator (tPA) and DNase, showing benefit in select populations by facilitating drainage in loculated collections and reducing the need for surgery. The gene discussed is PLAT; the disease is empyema.